News

Filter

Current filters:

GlaxoSmithKlineBenlysta

31 to 39 of 39 results

GlaxoSmithKline and Human Genome fall as US FDA questions lupus drug candidate Benlysta

15-11-2010

Ahead of an advisory panel review tomorrow (November 16), the US Food and Drug Administration posted…

BenlystaGlaxoSmithKlineHuman Genome SciencesImmunologicalsNorth AmericaPharmaceuticalRegulation

GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019

10-08-2010

Driven primarily by the launch and uptake of Human Genome Sciences and GlaxoSmithKline's Benlysta (belimumab),…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMabTheraMarkets & MarketingPharmaceuticalRituxan

Lonza to produce lupus drug Benlysta for GlaxoSmithKline/Human Genome Sciences

13-07-2010

Human Genome Sciences has entered into an agreement with Switzerland-based chemical company Lonza for…

BenlystaFinancialGlaxoSmithKlineHuman Genome SciencesImmunologicalsLonzaPharmaceutical

US rheumatologists express significant interest in Benlysta, the first novel drug for lupus in decades

16-06-2010

Preliminary findings indicate that, despite the availability of multiple treatment options, most of which…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRegulation

Merck Serono resubmits cladribine as a potential MS therapy in USA; GSK/HGS file Benlysta in Europe

08-06-2010

Putting it back in the race to get US approval for an oral multiple sclerosis treatment, Merck Serono,…

BenlystaCladribineGlaxoSmithKlineHuman Genome SciencesImmunologicalsMerck KGaAMerck SeronoNeurologicalPharmaceuticalRegulation

31 to 39 of 39 results

COMPANY SPOTLIGHT

Menarini

Back to top